Bot Image, Inc. – Trademark Portfolio

Entity Type: 03

Bot Image, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include MALESCAN, BOT IMAGE, and PROSTATID. The owner is based in Omaha, NE.

14301 FNB Parkway, Suite 109

Omaha, NE 68154

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Bot Image, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Bot Image, Inc. have?

Bot Image, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 1 abandoned.

What trademark classes does Bot Image, Inc. file in?

Bot Image, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Bot Image, Inc.'s most well-known trademarks?

Bot Image, Inc.'s registered trademark portfolio includes well-known marks such as MALESCAN, BOT IMAGE, and PROSTATID. These are among 3 currently registered trademarks in the portfolio.

What is Bot Image, Inc.'s trademark registration success rate?

Bot Image, Inc. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 1 application is pending review.